Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Supreme Court

Poll Finds Majority Want Obamacare Subsidies to Survive Supreme Court Case

Washington, DC, June 9, 2015The Hill reported that two-thirds of people hope that Obamacare subsidies will be upheld in court later this month, including nearly 50 percent of Republicans, according to a new poll.

A total of 61 percent of people said low-income Americans should be eligible for the subsidies regardless of what state they live in — a question at the center of the looming King v. Burwell case, according to the poll commissioned by the progressive group Americans United for Change. Continue reading

U.S. Supreme Court Lets Stand a California County Drug Disposal Law; PhRMA, BIO, GPhA Vow to Educate Consumers

Washington, DC, June 1, 2015 ― The Associated Press reported that the U.S. Supreme Court has let a Northern California county’s drug disposal law stand, paving the way for similar ordinances elsewhere.

The court refused to hear the pharmaceutical industry’s challenge to an Alameda County program that requires drug companies to pay for the disposal of unused medicines.

Drug companies estimate they will spend $1.2 million annually complying with the Alameda ordinance.  The county estimated a far smaller cost of $330,000 a year. Continue reading

Pharmalot: U.S. Supreme Court Says Pharmaceutical Industry Must Pay for Drug Take-Back Programs

New York, NY, May 27, 2015 The Wall Street Journal’s Pharmalot blog reports that, in a setback to drug makers, the U.S. Supreme Court yesterday denied an industry request to review a lawsuit filed over a drug take-back program in Alameda County, California.

The pharmaceutical industry had been fighting a three-year-old ordinance that requires drug makers to underwrite the costs of a program in which consumers can drop off unwanted medicines.

Fearing still more local governments would pass such ordinances and create added expenses, three industry trade groups — the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO) and the Generic Pharmaceutical Association (GPhA) — filed a lawsuit and argued the local law was unconstitutional.  Continue reading

NYT: On 5th Anniversary of Obamacare, No End to Debate

Washington, DC, March 23, 2015 The New York Times reports that when President Barack Obama signed the Affordable Care Act five years ago today, he visualized a time when the political hyperbole would be silenced and ordinary people would see that the health care law improved their lives.

The White House ceremony on March 23, 2010, was an applause-filled celebration. “When I sign this bill,” Obama said, “all of the overheated rhetoric over reform will finally confront the reality of reform.” Continue reading

Kaiser Family Foundation Poll: If Supreme Court Rules Against Obamacare Subsidies, Most Want Them Restored

Washington, DC, January 28, 2015 ― Kaiser Health News reports that a new poll finds that most people think Congress or states should act to restore health insurance subsidies if the U.S. Supreme Court decides later this year they are not permitted in states where the federal government is running the marketplace.

The court in March is set to hear King v. Burwell, a lawsuit arguing that the wording of the Affordable Care Act means that financial assistance with premiums is available only in the 13 states that created and are running their own online insurance exchanges.

If the court sides with those challenging Obamacare, millions of people in the 37 states that use the federal Healthcare.gov site would lose the help they have been getting.  A decision in the case is expected in late June. Continue reading

Biopharma Trade Groups Ask US Supreme Court to Review California County Drug Take-Back Program

New York, NY, January 7, 2015 ― Pharmalot reports that, angry over a drug take-back program instituted by a California county, the pharmaceutical industry has asked the US Supreme Court to review the constitutionality of the program.

In a filing on December 29, three trade groups — the Pharmaceutical Research and Manufacturers of America (PhRMA), the Generic Pharmaceuticals Association (GPhA) and the Biotechnology Industry Organization (BIO) — argue that a federal appeals court erred last September when it upheld a lower-court ruling that the program did not violate the Constitution.

The trade groups maintain that Alameda County interfered with interstate commerce and discriminates against out-of-state drug makers. Continue reading